The study will seek to further characterize any other serious adverse reactions in the long-term in adults with prostate cancer who received at least one dose of 177Lu-PSMA-617 from interventional, phase I-IV Novartis sponsored clinical trials. This evidence concerns the gene FOLH1 and prostate carcinoma.